Infertility Clinical Trial
Official title:
Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation for Poor Responders in ICSI Cycles
Objective: To compare two stimulation protocols, the minidose long protocol and the
microdose flare protocol designed for low responders undergoing ICSI.
Design: Randomized prospective study. Setting: University hospital IVF unit. Patients: 60
poor responder patients coming for IVF center for ICSI. Interventions: Minidose long
protocol in which half the dose of agonist was administered from the mid luteal phase until
the day of HCG administration was compared with microdose flare protocol in which half the
dose of GnRH was administered from the second day of the cycle until the day of HCG
administration. Both groups received Gn stimulation from the second day of the cycle
(300-450 IU).
Main outcome measures: Number of oocytes retrieved.
Patients and methods:
60 patients expected to have poor response for ovarian stimulation attending kasr EL-Aini
hospital IVF center planning for ICSI during the year 2011 were randomized to receive
ovulation induction for controlled ovarian hyperstimulation by either one of two protocols:
Minidose long protocol and microdose flare protocol.
Inclusion criteria:
All patients included were classified as poor responders when one of the following criteria
was present:
- Age > 35 years.
- Day 3 serum FSH level > 10m IU/ml.
- Number of antral follicles measuring 4-8mm during the early phase < 6.
- Small ovarian volume.
- AMH < 1.
- Prior poor ovarian response to COH (oocytes < 5).
Exclusion criteria:
- Polycystic ovarian syndrome patients.
- Patients with Endometriosis.
- Normal responders to ovulation induction.
- Patients having ovarian cyst.
- Patients receiving ovulation induction in the preceding cycle. The study was approved
by Kasr El-Aini IVF center research committee. Each patient had given informed consent
after full explanation of the procedure. Randomization was performed according to a
computer generated list. The patients were randomized to two groups.
The Minidose long protocol:
Decapeptyl 50µg/ day was administered SC from cycle day 21 until menstruation. On the second
day of the cycle, patients were assessed for downregulation; E2 level < 50 pg/ml,
endometrial thickness less than 5 mm, no follicles > 15mm. Once patient downregulation was
confirmed, Gn dose was commenced at an initial dose of 300-450 IU/day for the first 5 days
followed by individual adjustment in Gn dose according to ovarian response and the dose of
Decapeptyl 50µg/day was continued until day of HCG administration.
The microdose flare protocol:
Administration of OCP's at the prior menses followed by Decapeptyl 50µg/day SC started on
the second day of the cycle and continued until the day of HCG administration. Gn was
started concomitantly on the second day of the cycle as described above.
Cycle monitoring:
Monitoring consisted of several ultrasound examination and serum E2 level in both protocols.
The starting Gn dosage was determined by a combination of factors including patient age,
ovarian reserve testing, prior stimulation response and was adjusted according to individual
response. Serum LH levels were measured from day 6 of stimulation to exclude premature
luteinization (LH > 15 IU/L).
10,000 IU HCG was administered intramuscular when at least two leading follicles were 18mm
in diameter. Oocyte retrieval was performed 35 hours after HCG administration by ultrasound
guided transvaginal aspiration.
Laboratory procedures:
The ICSI procedure was performed 4 hours after oocyte aspiration for all the mature oocytes.
Fertilization was assessed 16-18 hours after ICSI and was considered normal only when two
distinct pronuclei were present. The embryos obtained were categorized on day 2-3 into 3
grades depending on their morphological appearance, zonal thickness, cytoplasmic
fragmentation and blastomere size.
Transfer procedure and luteal support:
Depending on patient age, embryo quality and the number of embryos available, 1-4 embryos
were transferred 2-3 days after oocyte collection under transabdominal ultrasound guidance
using a cook catheter.
The luteal phase was supported with micronized progesterone 400 mg twice daily administered
vaginally until a pregnancy test was performed.
Outcome measures:
To assess a difference in pregnancy rates between the two protocols, a sample size of 100's
of patients should be considered but considering the size of our work, it would be many
years before such large samples could be recruited. We therefore chose to focus on oocyte
number as a main outcome measure.
The data recorded for analysis included: age, infertility history and etiology, day 3 FSH,
duration of stimulation, number of gonadotrophin ampoules required, E2 level on the day of
HCG administration, number of oocytes retrieved and fertilized and number of embryos
transferred.
The primary outcome measure was the number of oocytes retrieved. The secondary outcome
measures were implantation and clinical pregnancy rates. A clinical pregnancy was defined as
a normal gestational sac measured with transvaginal ultrasound after 5 weeks.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |